Authors: Holly A. Jensen, Lauren E. Styskal, Ryan Tasseff, Rodica P. Bunaciu, Johanna Congleton, Jeffrey D. Varner, Andrew Yen
DOI: 10.1371/journal.pone.0058621
Abstract Summary
Researchers developed retinoic acid (RA)-resistant leukemia cell lines to understand treatment failure mechanisms. While resistant cells lost key differentiation markers like growth arrest and CD11b expression, they retained some RA responses. Importantly, inhibiting Src-family kinases restored multiple differentiation features, suggesting RA resistance develops gradually and may be reversible.
Why Brain? ðŸ§
PP2 inhibitor restores differentiation in retinoic acid-resistant leukemia cells by rescuing cell cycle arrest and surface markers, offering new therapeutic approach for drug-resistant cases.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
